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PChronic Coronary Artery Disease
New Anatomic Score for
rognosis After Cardiac Catheterization
n Patients With Previous Bypass Surgery
awrence Liao, MD,* David F. Kong, MD,* Linda K. Shaw, MS,* Michael H. Sketch, JR, MD,*
armelo A. Milano, MD,† Kerry L. Lee, PHD,* Daniel B. Mark, MD, MPH*
urham, North Carolina
OBJECTIVES The purpose of this study was to determine the value of a new anatomic score for prognosis
after diagnostic catheterization in patients with previous coronary artery bypass grafting
(CABG).
BACKGROUND Previous CABG patients comprise a growing proportion of patients with coronary artery
disease (CAD). Whereas prognostic scores are available to adjust for native CAD, there are
no comparable scores for patients with previous CABG.
METHODS We studied 3,178 previous CABG patients (2,729 in a training set) who underwent cardiac
catheterization. With a Cox model to develop relative weights in the training set, we created
a graft index that adjusted native anatomy for territories with grafts free of significant (75%)
stenoses. Scaling the regression coefficients by the maximum coefficient created an index
ranging from 0 to 100, where 100 was three-vessel CAD with no patent grafts.
RESULTS The graft index was significantly associated with all-cause death (chi-square  121.9, p 
0.001). In combined models, the index was more strongly associated with all-cause death than
either number of diseased vessels (chi-square 68.0 and 1.7, respectively) or the Duke CAD
index (chi-square  54.3 and 9.5, respectively). In models for death using an independent
validation set, the index was also associated more strongly than either native disease
descriptors. In a model including other clinical variables, the graft index remained signifi-
cantly associated with all-cause death (chi-square  40.1, p  0.001).
CONCLUSIONS For previous CABG patients, the Duke graft index was significantly more associated with
prognosis than native anatomy alone and quantifies the effect of patent grafts on survival. This
tool has the potential to help determine prognosis and inform the referral of post-CABG
patients to repeat revascularization procedures. (J Am Coll Cardiol 2005;46:1684–92)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.074© 2005 by the American College of Cardiology Foundation
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lith more than 500,000 procedures performed annually,
oronary artery bypass grafting (CABG) is now the most
ommon major operation in the U.S. (1). Unfortunately,
ABG does not permanently solve the problem of coronary
rtery disease (CAD). Managing patients with previous
ABG and recurrent symptoms poses a growing clinical
hallenge. Acute coronary syndromes, percutaneous revas-
ularization procedures, and redo surgery all have higher
omplication rates for patients who have previously under-
one CABG (2–9).
These sobering statistics underscore the need for accurate
nd rational treatment selection for these patients when they
eturn to the health care setting years after CABG with
ecurrent symptoms. Decisions about which patients might
enefit the most from further revascularization procedures
an be made in an informed way only if clinicians have
dequate risk stratification tools.
From the *Duke Clinical Research Institute and †Department of Surgery, Duke
niversity Medical Center, Durham, North Carolina. This work was supported
hrough the Duke Clinical Research Institute and a Duke Heart Center Initial Career
ward (to Dr. Kong). This work was presented in abstract form at the Americant
eart Association 2002 Annual Scientific Sessions.
Manuscript received April 27, 2005, accepted June 9, 2005.Although several angiographic schemes have been devel-
ped to describe native coronary anatomy, we are unaware
f any published efforts to stratify patients with previous
ABG by angiography accounting for graft patency. Given
he significant impact of coronary anatomy on prognosis, an
mproved anatomic scheme that accounts for graft patency
ould be an important initial step in developing compre-
ensive risk-adjustment tools for such patients. Moreover,
elating coronary anatomy to survival with medical therapy
lone would be a critical prelude to understanding the
enefits of further revascularization. In this study, we
eveloped and validated a new experience-based anatomic
core for prognosis in patients with previous CABG.
ETHODS
atient population. With the Duke Cardiovascular Dis-
ase Databank, we identified patients with at least one
revious CABG (i.e., any patient with a previous CABG
as eligible for inclusion) who underwent diagnostic cardiac
atheterization between January 1, 1986, and December 31,
001. After their index catheterization, patients were fol-
owed at six months and annually for mortality status by
elephone contact, mailed questionnaire, and National
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November 1, 2005:1684–92 New Anatomic Score for Prognosiseath Index search. The methods used by the Cardiovas-
ular Databank have been described previously (10,11).
We excluded patients with previous valve surgery, mod-
rate or severe valve disease, or congenital heart disease.
uring the study period, 55,602 diagnostic catheterizations
ere performed on patients without these exclusions. Of
hese, there were 7,031 catheterization procedures in 4,330
nique patients who had previously undergone CABG. We
ncluded only first catheterizations. Data from second or
ubsequent catheterizations were excluded. In these 4,330
atients, we excluded 497 patients with sequential (jump) or
grafts, because these grafts frequently spanned two ana-
omic territories and were, therefore, difficult to credit in our
cheme (see following description). We further excluded
55 patients with incomplete graft data. There were 3,178
atients in the final analysis set. Before analysis, the popu-
ation was divided by random assignment into a 2,729-
atient training set and a 449-patient validation set.
evelopment. Our objective was the development of an
natomic score for prognosis in patients with previous
ABG. We used the clinical outcomes of the population to
erive the index values (an “experience-based” approach),
reating a score for relating the different classes to one
nother (12). An alternative (“rule-based”) approach (exam-
les for native coronary anatomy include Gensini and Green
ane Hospital scores) would be to specify a set of rules that
escribe the hierarchy. Because a rule-based approach does
ot lend itself to “scaled” measurements of how different
lasses relate to one another, even though the classes might
e correctly ranked, we chose to create the graft index with
n experience-based method.
We developed the graft index in the training set using five
teps. First, we grouped training-set patients into disease
ategories according to the number of diseased native
oronary territories (one, two, or three). Patients with left
ain disease were initially considered to have at least two
iseased territories (three, if there was also significant right
oronary artery [RCA] disease). We then subdivided these
roups into subcategories, using the number of protected
erritories. Each territory with native disease was considered
rotected if it had at least one patent, non-significantly
iseased (75% stenosis) graft. No credit was given for
dditional grafts to a protected territory. Territories without
ignificant disease could not be considered protected.
herefore, patients with one-vessel native disease could
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CAD  coronary artery disease
IMA  internal mammary artery
LAD  left anterior descending coronary artery
MI  myocardial infarction
RCA  right coronary artery
SVG  saphenous vein graftave either zero or one protected territory (making two pubcategories). Patients with two-vessel native disease could
ave zero, one, or two protected territories (making three
ubcategories). Patients with three-vessel native disease
ould have zero, one, two, or three protected territories
making four subcategories).
These categories were entered as individual variables into
Cox proportional hazards regression model for mortality
o determine their relative weights. Time zero for all models
as date of diagnostic catheterization. Index values for each
ategory were obtained by dividing each regression coeffi-
ient by the largest regression coefficient (for three-vessel
ative disease with no protected territories), multiplying by
00, and rounding to the nearest integer. Because of the
lose approximation in their index values, the lowest two
ategories (one-vessel disease with no protected territories
nd one-vessel disease with one protected territory) were
ombined for further analyses. The proportional hazards
ssumption was checked with the combination of an inter-
ction test with time and stratified Kaplan-Meier curves.
here were no obvious violations of the assumption.
To further quantify the independent contributions of
ignificant left main coronary disease and in situ (i.e., not
free”) internal mammary artery (IMA) grafts in the Cox
odel, we included separate indicator variables for each. We
id not have enough patients in our dataset with free IMA
rafts to examine their utility separately. For both left main
isease and IMA grafts, this produced parameter estimates
hat could be scaled as an adjustment factor to the graft index.
A series of Cox models tested the association of this index
o outcome relative to two other CAD descriptors: number
f diseased native vessels and the Duke CAD index. The
erivation of the Duke CAD index has been described
reviously (13). The primary end point for our analysis was
ll-cause death. Patients were censored at the time of
ardiac revascularization procedures.
With the training set, Cox model sensitivity analyses were
erformed to test the index model assumptions. The defi-
ition of graft patency was varied (50%, 95%, 100%
tenosis). The independent effect of grafting specific terri-
ories (left anterior descending coronary artery [LAD],
CA, and left circumflex coronary artery) was assessed by
pecifying indicator variables for each territory.
alidation. Because models evaluated in their derivation
opulation tend to provide an overly optimistic assessment
f their performance, after all assumption testing and
ensitivity analyses were completed, the index was validated
ith two methods. First, we examined the prognostic value
f the index in a series of Cox models using the patient set
validation set) not previously used to fit the model (split-
ample validation). This validation technique has been used
reviously at our institution (14,15). Second, the index was
alidated internally with bootstrap estimation of the entire
atient sample.
Finally, after all other analyses were completed, to ensure
hat the weights of the index were based on all the available
rognostic information, the index, left main, and IMA
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New Anatomic Score for Prognosis November 1, 2005:1684–92orrection factors were recalculated using all 3,178 patients.
his recalculated index was subsequently included in a series
f Cox models with other clinical variables to assess its
dded prognostic value for both all-cause death (censoring
n revascularization) and the combined end point of death
r revascularization. Analyses were performed with SAS
tatistical software (SAS Institute, Cary, North Carolina).
ESULTS
he baseline characteristics of the 3,178 patients in the
nalysis set are shown in Table 1. The majority were men
71%) and Caucasian (86%). The median age was 63 years.
n this post-CABG population, 66% had three-vessel native
oronary disease and 61% had a history of myocardial
nfarction (MI). The majority of patients (98%) had a
istory of angina, and most (80%) had experienced angina
ithin six weeks of catheterization. Left IMA grafts were
resent in 46%, and right IMA grafts were present in 4%.
atients underwent cardiac catheterization a mean of 4.1
ears (median 2.8 years) after CABG (Table 2).
During the follow-up period (1986 to 2002), 601 patients
ied (529 in the training set and 72 in the validation set).
ithin 30 days of diagnostic catheterization, 954 patients
nderwent percutaneous coronary intervention and 192
atients underwent redo CABG. Patients selected for redo
ABG were more likely to have three-vessel disease (78%
ompared with 66% in the complete cohort) and were less
ikely to have an intact left IMA graft (12% compared with
1% among patients not receiving redo CABG).
The initial graft index categories with corresponding
ndex values (0 to 100), hazard ratios, and survival estimates
able 1. Baseline Characteristics
Characteristic (%)
All Patients
n  3,178
ge (yrs), median (25th, 75th) 63 (55, 70)
aucasian 86.1
ale 71.3
istory of PCI 24.4
istory of stent 6.5
ypertension 67.3
arotid bruits 18.3
harlson index 1 24.1
HF 30.3
lass IV CHF 5.5
istory of angina 97.7
ngina in previous 6 weeks 79.8
iabetes 32.3
erebrovascular disease 16.7
OPD 8.1
eripheral vascular disease 20.5
revious myocardial infarction 60.6
yperlipidemia 68.0
istory of smoking 70.8
ymptom duration (months), median (25th, 75th) 78 (28, 139)
pisodes of pain per week, median (25th, 75th) 4 (2, 7)
ime since prior CABG (yrs), median (25th, 75th) 2.8 (0.7, 6.4)e
ABG  coronary artery bypass graft; CHF  congestive heart failure; COPD 
hronic obstructive pulmonary disease; PCI  percutaneous coronary intervention.re shown in Table 3. Column one displays the index values
alculated with only the training sample patients. As ex-
ected, patients with three-vessel disease and no protected
erritories (no patent grafts) had the worst prognosis and the
ighest index value, 100. Patients with one-vessel disease
with or without a protected territory) had the best prog-
osis and the lowest index value, 34. Kaplan-Meier curves
or patients with one- or two-vessel native disease are shown
n Figure 1. Kaplan-Meier curves for patients with three-
essel disease are shown in Figure 2. These survival curves
emonstrate how accounting for graft patency identifies
opulations with different mortality risk within each cate-
ory of native disease.
MA and left main effects. In Cox models including the
ase version of the graft index, presence of a patent IMA
Wald chi-square 18.1, p 0.0001) and left main disease
Wald chi-square  15.4, p  0.0001) were each signifi-
antly associated with survival. For this end point, the graft
ndex adjustment for a patent IMA compared with a patent
aphenous vein graft (SVG) was 24, and the adjustment
or significant left main disease was 28 (Table 4). The
MA correction factor is substantial enough that a patent
MA confers as much or even more survival benefit than
wo patent SVGs at each level of native disease (Table 4).
he benefit of an IMA graft is demonstrated in the better
urvival for patients with two-vessel native disease with one
erritory protected by an IMA graft and one territory
rotected by an SVG, compared with patients with similar
ative disease and either both territories protected by SVGs
r no patent grafts (Fig. 3). Similarly, the left main
orrection (in addition to the base assumption of assuming
eft main disease was equivalent to two-vessel disease) is
able 2. Baseline Catheterization Data
Characteristic (%)
All Patients
n  3,178
o. of diseased vessels
0 (no significant disease) 1.2
1 9.3
2 23.6
3 65.9
ignificant left main disease 13.9
rafts to LAD 86.8
rafts to right coronary 72.1
rafts to left circumflex 75.2
ignificant disease in LAD graft 32.2
ignificant disease in RCA graft 43.9
ignificant disease in LCX graft 46.2
otal occlusion in LAD graft 20.0
otal occlusion in RCA graft 31.5
otal occlusion in LCX graft 29.3
eft internal mammary artery 46.0
ight internal mammary artery 3.7
jection fraction, median (25th, 75th) 53 (42, 62)
itral insufficiency 1/2 25.1
AD  left anterior descending artery; LCX  left circumflex coronary artery; RCA 
ight coronary artery.ven larger in effect. Table 4 shows the index values
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November 1, 2005:1684–92 New Anatomic Score for Prognosisecalculated with all patients (training and validation
amples).
raining set models. In the training set, the graft index
as more strongly associated with prognosis than either
umber of diseased vessels (incremental chi-square  53.6,
 0.001) or a more sophisticated native disease descriptor,
he Duke CAD index (incremental chi-square  40.2, p 
.001) (Table 5). In combination with number of diseased
essels, only the graft index remained significantly associ-
ted with death (p  0.0001). The combination model that
ncluded both the Duke CAD index and the graft index had
he highest model chi-square values (log-rank chi-square 
18.4) with both variables retaining prognostic importance
p  0.0018 and 0.0001, respectively).
ensitivity analyses. Varying the definition of graft pa-
ency from 50% to 100% stenosis did not substantively
lter our models. The model using our preferred definition
f patent, insignificantly diseased grafts (75% stenosis)
able 3. Graft Index for All-Cause Death Without Left Main or
Index Value Training
Set Patients Only Patient Category
0 No significant disease
34 1-vessel with 1 protected territory 1
54 2-vessel with 2 protected territories 2
64 3-vessel with 3 protected territories 2
68 2-vessel with 1 protected territory 3
78 2-vessel with 0 protected territory 3
81 3-vessel with 2 protected territories 4
88 3-vessel with 1 protected territory 5
100 3-vessel with 0 protected territory 6
urvival data calculated from all patients (training and validation sets).
CI  confidence interval; IMA  internal mammary artery.Figure 1. Survival by graft index value for patients with one- anas the one with the highest association with outcome as
xpressed by the model chi-square values. The individual
erritories grafted (LAD, left circumflex coronary artery,
CA) also had little independent effect on the model. In
odels including the graft index and variables for patent
rafts to each of the three territories (log-rank chi-square 
27.7 with 4 degrees of freedom), only the graft index
log-rank chi-square  108.2, p  0.001) was significantly
ssociated with outcome.
odel validation: independent test set. In models gen-
rated with the validation sample, the graft index again
emonstrated significant independent association with
eath (Table 6). Compared with a model with number of
iseased vessels alone, the graft index model had larger
hi-square values and an incremental chi-square  14.3 (p
0.001). In the models combining graft index with the
ative disease descriptors, only the graft index remained a
ignificant independent variable.
Adjustment
rd Ratio
% CI) 3-Yr Survival 5-Yr Survival 7-Yr Survival
NA 100 95.7 95.7
.64–4.95) 90.9 86.2 81.5
.90–6.69) 90.6 83.7 78.4
.07–7.86) 88.4 83.7 72.4
.22–9.24) 86.0 77.7 67.2
.26–10.9) 80.2 78.1 72.9
.58–11.6) 80.8 70.4 60.1
.90–14.0) 81.0 63.4 51.5
.43–18.0) 75.1 60.7 46.8IMA
Haza
(95
.78 (0
.46 (0
.90 (1
.35 (1
.70 (1
.28 (1
.16 (1
.61 (2d two-vessel native disease (1 vd and 2 vd, respectively).
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New Anatomic Score for Prognosis November 1, 2005:1684–92ootstrap validation. In addition to the split-sample val-
dation, we also examined the graft index with bootstrap
stimation. After 600 samples, the observed statistic and the
ootstrap mean were the same (0.02). The confidence
nterval was very small (0.01 to 0.02) with a small approx-
mate bias (0.00005). These results indicate a stable model
ith good validation.
dded prognostic value of the graft index. In a Cox
odel for all-cause death that also included age, gender,
ace, diabetes mellitus, hypertension, congestive heart fail-
re, peripheral vascular disease, cerebrovascular disease,
moking, S3 gallop, previous MI, time since CABG, and
resentation with acute coronary syndrome, the graft index
emained significantly associated with outcome (chi-square
38.8, p  0.0001). These data are shown in Table 7. In
model created by stepwise selection at the 0.05 signifi-
ance level that included age, congestive heart failure,
iabetes, peripheral vascular disease, time since CABG, S3
Figure 2. Survival by graft index value for
able 4. Graft Index With Left Main and Internal Mammary A
Index Value Patient Category No Adj
0 No significant disease 9
31 1-vessel with 1 protected territory 8
48 2-vessel with 2 protected territories 8
56 3-vessel with 3 protected territories 8
64 2-vessel with 1 protected territory 7
69 2-vessel with 0 protected territory 7
77 3-vessel with 2 protected territories 7
87 3-vessel with 1 protected territory 6
100 3-vessel with 0 protected territory 6he index score should be adjusted by 24 points for patients with territory protected by a
oints for patients with significant left main disease.allop, and previous MI, the graft index retained its prog-
ostic significance (Wald chi-square  40.1, p  0.0001).
he only clinical variables with higher chi-square values
ere age and congestive heart failure. In a model combining
he graft index and these clinical variables, the corrected
-index by bootstrap estimation improved from 0.63 to 0.73.
Although the graft index was designed for the end point
f all-cause death, we also examined its prognostic power
or the combined end point of death or revascularization.
or this end point, the graft index (chi-square 287.7, p
.0001) had stronger univariate association with outcome
larger chi-square) than either number of diseased vessels
chi-square  75.1) or the Duke CAD index (chi-square 
7.9). In combined models, the graft index proved substan-
ially more powerful than either descriptor of native disease.
ombining the graft index with number of diseased vessels,
he Wald chi-square values were 211.7 and 5.0, respectively.
ombining the graft index with the CAD index, the chi-
ts with three-vessel native disease (3 vd).
ents Recalculated Using All Patients
ents
5-Yr Survival
With Left Main Disease With Intact IMA Graft
N/A N/A
N/A 88.3
65.3 86.5
67.8 87.1
76.2 80.0
71.2 N/A
62.9 74.0
63.3 66.1
50.0 N/Adjustm
ustm
5.7
6.2
3.7
3.7
7.7
8.1
0.4
3.4
0.7patent, non-significantly diseased internal mammary artery (IMA) graft and by 28
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November 1, 2005:1684–92 New Anatomic Score for Prognosisquare values were 195.8 and 1.3, respectively. In the multiva-
iable models that also included age, gender, race, diabetes
ellitus, hypertension, congestive heart failure, peripheral
ascular disease, cerebrovascular disease, smoking, S3 gallop,
revious MI, time since CABG, and presentation with
cute coronary syndrome, the graft index remained inde-
endently associated with outcome (Wald chi-square 
68.3, p  0.0001). In the model created by stepwise
election of significant covariates that included acute coro-
ary syndrome, time since CABG, diabetes, peripheral
ascular disease, and hypertension, the graft index was the
ariable most strongly associated with death or revascular-
zation (chi-square  172.1, with all other variables chi-
quare 35). These data are shown in Table 8.
ISCUSSION
his study demonstrates the prognostic value of a new
tatistical index for estimating the survival of patients after
igure 3. Survival comparison for patients with intact internal mamma
isease.
able 5. Training Set Models for All-Cause Death (n  2,729)
Models
Wald
Chi-Square p
Model LR
Chi-Square
ne-variable models
No. diseased vessels 48.7 0.0001 56.1
Graft index 106.8 0.0001 108.5
CAD index 71.4 0.0001 78.2
ombination models
No. diseased vessels 1.2 0.2712 109.7
Graft index 53.9 0.0001
CAD index 9.8 0.0018 118.4
Graft index 40.5 0.0001AD  coronary artery disease; LR  log rank. AABG. The index has two components: one that estimates
he benefit of all patent grafts in the setting of native disease
Table 3) and an additional adjustment that accounts for the
enefit of IMA grafts, which is applied if an IMA graft is
resent (Table 4). By accounting for graft patency, models
ncluding this statistical index outperformed models using
escriptors of diseased native vessels alone. Although graft
natomy is only one of several variables associated with
ortality, this index significantly improves upon the current
tandard models that do not account for graft patency. In
ddition, the index retains statistical significant association
ith outcomes even after adjustment for native disease
escriptors and other clinical variables.
otential clinical application. The graft index estimates
atient survival with medical therapy at several levels of
ative and graft disease. Whereas the index should prove
seful to researchers investigating the post-CABG popula-
ion, we hope that this tool will also be applied clinically in
tery (IMA) graft. SVG  saphenous vein graft; 2 v/vd  two-vessel
able 6. Validation Set Models for All-Cause Death (n  449)
Models
Wald
Chi-Square p
Model LR
Chi-Square
ne variable models
No. diseased vessels 2.1 0.1430 2.3
Graft index 15.3 0.0001 15.5
CAD index 2.9 0.0886 3.0
ombination models
No. diseased vessels 1.1 0.2994 16.6
Graft index 14.0 0.0002
CAD index 0.4 0.5257 15.9
Graft index 12.6 0.0004bbreviations as in Table 5.
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New Anatomic Score for Prognosis November 1, 2005:1684–92uiding the management of post-CABG patients with
ecurrent symptoms. Like other approaches to risk stratifi-
ation, the primary value of the graft index is the identifi-
ation of patients that are at low risk despite their serious
AD and, therefore, might not benefit from additional
evascularization. For example, patients with two-vessel
AD and territories protected by an intact IMA and SVG
graft index value  24) have a five-year mortality of 13%
annual mortality approximately 3%). Although this would
ardly be considered “low-risk” in a general population,
ecause the observed five-year mortality rates after repeat
ABG or percutaneous coronary intervention (after previ-
us CABG) in the Emory series are 24% (annual mortality
5%) and 22% (annual mortality approximately 5%), re-
pectively, such patients might benefit little from these
rocedures (6). In contrast, patients with three-vessel dis-
ase and one protected territory (graft index value  87)
ave a five-year mortality of 38% (annual mortality approx-
mately 9%) and would be likely to benefit from repeat
evascularization.
able 7. Models for All-Cause Death With the Graft Index and
Variables
Full Model
Hazard Ratio Wald Chi-Sq
ge (per 10 yrs) 1.53 78.7
ender (male) 0.91 0.9
ace (white) 1.11 0.6
iabetes 1.73 36.9
ypertension 1.18 3.0
ongestive heart failure 1.84 46.8
eripheral vascular disease 1.60 24.2
erebrovascular disease 1.00 0.1
moking 1.09 0.8
entricular gallop 1.77 15.8
istory of myocardial infarction 1.39 12.1
cute coronary syndrome 1.13 2.1
ime since previous CABG (yrs) 1.06 20.1
raft index (per point) 1.01 38.8
This variable dropped in stepwise selection model.
CABG  coronary artery bypass grafting.
able 8. Models for Death or Revascularization With the Graft
Variables
Full Model
Hazard Ratio Wald Chi-Sq
ge (per 10 yrs) 1.00 0.1
ender (male) 1.04 0.5
ace (white) 1.11 2.5
iabetes 1.17 10.5
ypertension 1.12 5.6
ongestive heart failure 0.98 0.2
eripheral vascular disease 1.13 4.8
erebrovascular disease 1.06 0.9
moking 0.99 0.1
entricular gallop 1.01 0.1
istory of myocardial infarction 1.05 1.1
cute coronary syndrome 1.28 28.9
ime since previous CABG (yrs) 1.03 30.0
raft index (per point) 1.01 168.3This variable dropped in stepwise selection model.
CABG  coronary artery bypass grafting.revious work. Patients who have undergone CABG ex-
ibit different outcomes than those patients without a
istory of surgical revascularization. Post-CABG patients
ho present for acute coronary syndromes, percutaneous
evascularization procedures, and redo surgery all have
igher complication rates (2–9). Because the benefit of
ABG intuitively derives from the patency of the bypass
rafts, it is not surprising that graft atherosclerosis causing
oss of patency impacts outcomes. In their angiographic and
athologic study of 50 post-CABG patients who experi-
nced acute MI, Grines et al. (16) demonstrated that the
ulprit vessel was usually (76%) an SVG rather than a native
essel. Similarly, several studies have shown that progressive
cclusion of grafts parallels the decline in survival in the
ears after CABG (3). Lytle et al. (17), examining the
utcomes of 723 post-CABG patients with SVG stenosis
nd 573 post-CABG patients without SVG stenosis, found
hat patients with stenosis in vein grafts to the LAD fared
orse than other patients. In contrast, Mehta et al. (18)
ound in a study of patients sent for redo CABG that
ical Variables
Model After Stepwise Selection
p Hazard Ratio Wald Chi-Square p
0.0001 1.53 81.8 0.0001
0.3309 * * *
0.4303 * * *
0.0001 1.73 39.2 0.0001
0.0849 * * *
0.0001 1.82 45.2 0.0001
0.0001 1.65 29.9 0.0001
0.9776 * * *
0.3747 * * *
0.0001 1.77 16.0 0.0001
0.0005 1.41 13.5 0.0002
0.1488 * * *
0.0001 1.05 20.2 0.0001
0.0001 1.01 40.1 0.0001
and Clinical Variables
Model After Stepwise Selection
p Hazard Ratio Wald Chi-Square p
0.8301 * * *
0.5009 * * *
0.1137 * * *
0.0012 1.18 11.7 0.0006
0.0178 1.12 5.4 0.020
0.6768 * * *
0.0285 1.13 5.4 0.020
0.3543 * * *
0.7965 * * *
0.9121 * * *
0.2906 * * *
0.0001 1.29 31.3 0.0001
0.0001 1.03 33.5 0.0001
0.0001 1.01 172.1 0.0001Clin
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ein grafts was uncommon.
Despite the significant influence of bypass grafts on
atient outcomes, previous studies on post-CABG patients
ave not attempted to account for graft patency (6,7,19–
2). Often, angiographic schemes to risk stratify CAD
atients have excluded patients with grafts (23–25). Given
he complexities of graft anatomy, the exclusion of post-
ABG patients is not surprising.
Nevertheless, such an oversight comes at a price: this
tudy demonstrates that a simple scheme accounting for
raft patency adds significant prognostic information to
umber of diseased native vessels alone. The graft index is
ore powerfully associated with death than a more detailed
ative disease descriptor, the Duke CAD index; however, in
combined model, both the CAD index and graft index
ontribute significant quantities of information. This is
ikely because the CAD index and the graft index are
ssessing different patient characteristics. Specifically,
hereas the CAD index identifies crucial aspects of native
natomy including stenosis severity and proximity to vessel
rigin, the graft index adds the prognostic information from
imple graft patency.
Is it possible to incorporate these properties into a single,
niversal model? Attempting to account for all the permu-
ations of graft anatomy, age, type, diameter, insertion,
edundancy, and disease would not be simple. The history of
natomic scoring for native coronary disease has illustrated
his problem: none of the various schemes to replace the
amiliar number of diseased vessels has gained widespread
linical acceptance. As information technology continues to
mprove, sophisticated models will doubtless become more
ortable, practical, and clinically applied. In the interim, we
hose to narrow our efforts to examine only selected issues
elated to graft benefit.
odel assumptions. The importance of subclinical vein
raft lesions remains controversial. Although Campos et al.
eported that vein grafts with insignificant disease six years
fter bypass were likely to still have insignificant disease an
dditional five years later, Ellis et al. (26) have demonstrated
hat untreated graft lesions of 51% stenosis are frequently
ssociated with subsequent adverse events (27). In their
nvestigation of patients presenting for second redo CABG,
oyez et al. (28) reported that by the time of second redo
mean 11 years after first CABG), most of the original
rafts had failed. In our sensitivity analyses, changing the
atency definition to 50% stenosis decreased the prognos-
ic power of the model (likely by introducing noise), whereas
iberalizing the patency definition all the way up to any open
raft failed to improve the model.
Some studies have suggested that patency rates are higher
or vein grafts to the LAD compared with grafts to other
erritories (3,29–31). In the Lytle et al. (17) study of
ost-CABG patients undergoing post-operative angiogra-
hy, they found that stenosis in LAD vein grafts was
ssociated with decreased re-operation and event-free sur- Cival compared with stenosis in grafts to other vessels. Lytle
t al. (17) included only patients with vein grafts (no
atients with IMA grafts) and excluded all patients who
nderwent revascularization within one year, who were
ithout graft stenosis or who had totally occluded grafts.
ecause the prognosis of MI also varies by territory, we
ested for territorial differences, using indicator variables for
ach. In our sample, territorial differences added no prog-
ostic information after accounting for IMA grafts. Despite
his result, given the preponderance of previous data, we
elieve that a larger sample of patients would likely find
erritorial differences in survival.
tudy limitations. There are several limitations to the
resent study. First, because the study examined symptom-
tic patients, our results should be generalized with caution
o asymptomatic post-CABG patients; however, because
ery few (if any) patients should undergo catheterization
ithout symptoms or signs of ischemia, we believe that our
esults should be generally applicable. Second, we only have
atheterization data from one institution. Data for patients
ho had CABG at our institution and underwent subse-
uent diagnostic catheterization elsewhere was not available
o us. Third, our study does not present a comprehensive
isk model for patients after CABG. Whereas many vari-
bles influence survival for patients after CABG, our model
ttempts only to demonstrate the prognostic power of
ngiographic anatomy. Fourth, by censoring on revascular-
zation procedures, our models only describe the effect of
edical treatment strategies on post-CABG survival. Other
on-fatal end points, such as non-fatal MI, were not
onsidered. Fifth, we lacked sufficient patients to examine
otential differences between free and in situ IMA grafts.
ixth, as with all retrospective analyses, we cannot fully correct
or the influence of possible informative censoring. To partially
ddress this issue, we have included analyses that use the
ombined end point of death and revascularization. As noted
reviously, this multivariable analysis reveals significant
hanges among important prognostic variables compared with
he results of the model for all-cause death. Despite the shifts
n clinical variables, in both models, the graft index remains
ignificantly associated with the outcome. Finally, whereas
he graft index might be useful for risk-stratification of
ost-CABG patients, it does not directly address the effect
f revascularization strategies on baseline risk. Additional
nalyses to assess these effects are underway.
onclusions. For patients with previous CABG who sub-
equently undergo cardiac catheterization, the Duke graft
ndex was significantly more associated with prognosis than
ative coronary anatomy alone. Although it remains to be
alidated in another large patient population, this tool has
he potential both to inform the management of patients
fter CABG and to improve the risk adjustment of these
atients in clinical studies. By demonstrating the different
edical treatment prognoses for patients with previous
ABG, our study provides a baseline reference for clinicians
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